Trial Profile
Distribution of the use of hexaminolevulinate (Hexyl aminolevulinate) in the diagnosis of non-muscle invasive bladder cancer (NMIBC): A prospective observational study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2018
Price :
$35
*
At a glance
- Drugs Hexyl aminolevulinate (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms HOPE
- 22 Jul 2018 New trial record